For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?
An open-label extension study of the PULSAR trial evaluated sotatercept treatment of patients with pulmonary arterial hypertension over 12 to 18 months.
Are delays in treatment for pulmonary arterial hypertension the cause of the poorer PAH outcomes seen among individuals in socially disadvantaged groups?
Findings of a long-term study on the safety and efficacy of ralinepag for pulmonary arterial hypertension are consistent with earlier clinical trial findings.
Can midodrine effectively stabilize blood pressure in patients with pulmonary arterial hypertension, thus enabling them to increase their PAH medication dosage?
In patients with pulmonary arterial hypertension, is abnormal pulmonary gas exchange during submaximal exercise associated with greater risk of clinical worsening events?
How is PAH severity related to peripheral endothelial dysfunction and arterial stiffness, and how does PAH treatment affect these variables?